Rana Sullivan

999 total citations
19 papers, 643 citations indexed

About

Rana Sullivan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Rana Sullivan has authored 19 papers receiving a total of 643 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Rana Sullivan's work include Prostate Cancer Treatment and Research (15 papers), PARP inhibition in cancer therapy (7 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Rana Sullivan is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), PARP inhibition in cancer therapy (7 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Rana Sullivan collaborates with scholars based in United States and Canada. Rana Sullivan's co-authors include Michael A. Carducci, Emmanuel S. Antonarakis, Hao Wang, Роберто Пили, Mario A. Eisenberger, Jun Luo, Benjamin A. Teply, Channing J. Paller, Patricia E. Cole and Serina King and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Rana Sullivan

19 papers receiving 635 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rana Sullivan United States	10	349	323	259	86	66	19	643
K. N. Canada	11	286 0.8×	213 0.7×	208 0.8×	144 1.7×	38 0.6×	21	509
Victoria Rimkunas United States	10	276 0.8×	225 0.7×	272 1.1×	108 1.3×	24 0.4×	26	556
Prateek Mendiratta United States	13	184 0.5×	256 0.8×	240 0.9×	118 1.4×	45 0.7×	37	584
Maria Thadani‐Mulero United States	7	307 0.9×	521 1.6×	203 0.8×	255 3.0×	84 1.3×	11	797
Vicki L. Gordon United States	10	309 0.9×	217 0.7×	112 0.4×	66 0.8×	70 1.1×	15	551
Brianne Kaiser United States	4	405 1.2×	132 0.4×	227 0.9×	97 1.1×	96 1.5×	4	607
Karin Welén Sweden	16	223 0.6×	249 0.8×	177 0.7×	150 1.7×	39 0.6×	20	488
Carolyn Evan United States	10	140 0.4×	387 1.2×	187 0.7×	168 2.0×	30 0.5×	20	527
Stuart McCracken United Kingdom	18	612 1.8×	375 1.2×	208 0.8×	149 1.7×	25 0.4×	37	1.0k

Countries citing papers authored by Rana Sullivan

Since Specialization

Citations

This map shows the geographic impact of Rana Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rana Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rana Sullivan more than expected).

Fields of papers citing papers by Rana Sullivan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rana Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rana Sullivan. The network helps show where Rana Sullivan may publish in the future.

Co-authorship network of co-authors of Rana Sullivan

This figure shows the co-authorship network connecting the top 25 collaborators of Rana Sullivan. A scholar is included among the top collaborators of Rana Sullivan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rana Sullivan. Rana Sullivan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Markowski, Mark C., Cora N. Sternberg, Hao Wang, et al.. (2024). TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations. The Oncologist. 29(9). 794–800. 7 indexed citations

Marshall, Catherine H., Benjamin A. Teply, Jiayun Lu, et al.. (2024). Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy. JAMA Oncology. 10(10). 1400–1400. 12 indexed citations

Marshall, Catherine H., Benjamin A. Teply, Su Jin Lim, et al.. (2023). Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.. Journal of Clinical Oncology. 41(16_suppl). 5087–5087. 4 indexed citations

Markowski, Mark C., Cora N. Sternberg, Hao Wang, et al.. (2023). TRIUMPH: Phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations.. Journal of Clinical Oncology. 41(6_suppl). 190–190. 6 indexed citations

Shenderov, Eugene, Karim Boudadi, Wei Fu, et al.. (2021). Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial. The Prostate. 81(6). 326–338. 47 indexed citations

Markowski, Mark C., Hao Wang, Rana Sullivan, et al.. (2020). A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology. 79(5). 692–699. 47 indexed citations

Antonarakis, Emmanuel S., Hao Wang, Benjamin A. Teply, et al.. (2019). Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.. Journal of Clinical Oncology. 37(15_suppl). 5045–5045. 15 indexed citations

Markowski, Mark C., Hao Wang, Rana Sullivan, et al.. (2018). Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).. Journal of Clinical Oncology. 36(15_suppl). TPS5095–TPS5095. 5 indexed citations

Teply, Benjamin A., Hao Wang, Rana Sullivan, et al.. (2018). Phase II study of olaparib (without ADT) in men with high-risk biochemically-recurrent prostate cancer following prostatectomy, with integrated biomarker analysis.. Journal of Clinical Oncology. 36(6_suppl). TPS386–TPS386. 1 indexed citations

10.

Teply, Benjamin A., Hao Wang, Brandon Luber, et al.. (2017). Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. The Lancet Oncology. 19(1). 76–86. 137 indexed citations

11.

Boudadi, Karim, Daniel L. Suzman, Brandon Luber, et al.. (2017). Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(15_suppl). 5035–5035. 24 indexed citations

12.

Teply, Benjamin A., Hao Wang, Rana Sullivan, et al.. (2017). Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza).. Journal of Clinical Oncology. 35(15_suppl). 5017–5017. 3 indexed citations

13.

Maughan, Benjamin L., Daniel L. Suzman, Brandon Luber, et al.. (2016). Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 78(6). 1297–1304. 21 indexed citations

14.

Boudadi, Karim, Daniel L. Suzman, Brandon Luber, et al.. (2016). STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 34(15_suppl). TPS5089–TPS5089. 1 indexed citations

15.

Park, Jong Chul, Oliver Sartor, Rana Sullivan, Serina King, & Emmanuel S. Antonarakis. (2015). Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 33(15_suppl). TPS5076–TPS5076. 7 indexed citations

16.

Siu, Lillian L., Роберто Пили, Ignacio Durán, et al.. (2008). Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 26(12). 1940–1947. 104 indexed citations

17.

Carducci, Michael A., Luna Musib, Merrill S. Kies, et al.. (2006). Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology. 24(25). 4092–4099. 150 indexed citations

18.

Messersmith, Wells A., Sharyn D. Baker, Rana Sullivan, et al.. (2006). Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.. Clinical Cancer Research. 12(4). 1270–1275. 44 indexed citations

19.

Carducci, Michael A., Lillian L. Siu, Rana Sullivan, et al.. (2006). Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3007–3007. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact